<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04185662</url>
  </required_header>
  <id_info>
    <org_study_id>T2DM20190619</org_study_id>
    <nct_id>NCT04185662</nct_id>
  </id_info>
  <brief_title>Effects of Artificial Sweeteners on Glucose Metabolism in Patients With Type 2 Diabetes</brief_title>
  <acronym>SWEETS</acronym>
  <official_title>Effects of Artificial Sweeteners on Glucose Metabolism in Patients With Type 2 Diabetes -A Multi-Center Randomized Controlled Clinical Trial(SWEETS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ShiBei Hospital , JingAn District, Shanghai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PuNan Hospital ,Shanghai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effects of artificial sweeteners on glucose metabolism in newly diagnosed
      type 2 diabetic patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Artificial sweeteners are among the most widely used food additives worldwide. Artificial
      sweeteners consumption is considered safe and beneficial owing to their low caloric content.
      However, recent studies demonstrated that consumption of commonly used artificial sweeteners
      formulations drives the development of glucose intolerance in healthy human subjects.
      However,the effects of artificial sweeter on glucose metabolism in newly diagnosed type 2
      diabetic patients remains unknown. Thus, different doses of sweeteners will be given to newly
      diagnosed type 2 diabetic patients to investigate the effects of artificial sweeteners on
      glucose metabolism.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>3 month</time_frame>
    <description>Fasting glucose change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postprandial blood sugar</measure>
    <time_frame>3 month</time_frame>
    <description>postprandial blood glucose change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>3 month</time_frame>
    <description>HbA1c change from baseline</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intake 200 ml water daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose sucrolose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intake 12.3mg sucralose in 200 ml water daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>moderate dose sucrolose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intake 73.8mg sucralose in 200ml water daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>sucralose</intervention_name>
    <description>daily intake different dose of artificial sweeteners sucralose or placebo</description>
    <arm_group_label>low dose sucrolose group</arm_group_label>
    <arm_group_label>moderate dose sucrolose group</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with newly diagnosed type 2 diabetes, diagnosed by World Health
             Organization criteria, were recruited from outpatient of the Endocrinology Department
             in Shanghai Renji Hospital, Shanghai PuNan hospital，Shanghai ShiBei hospital, shanghai
             xinhua hospital, chongming branch;

          -  FBG≤ 9 mmol/L, HbA1c≤ 7% ;without any oral hypoglycemic agents or insulin,

          -  Age ≥30 and ≤ 60 years old.

          -  BMI &gt;24 and &lt;28 kg/m2; --no regular consumption of artificial sweeteners or foods that
             have added much sweeteners.(eg:Coca-Cola zero), no sucralose intolerance.

        Exclusion Criteria:

          -  patients who had a history of acute and chronic diarrhea or constipation or severe
             chronic gastrointestinal disease..

          -  underwent enterectomy or other abdominal surgery (e.g., gallbladder removal) within
             one year;

          -  take antibiotics, antidiarrheic, antispasmodic, steroids and immune agents within
             three months.

          -  Patients who had a history of abnormal renal function(creatinine &gt;132μmol/L), active
             liver disease(ALT were 2.5 times higher than the normal upper limit), or accompany
             with other sever diseases, such as severe infection, severe anemia, neutropenia and
             mental illness.

          -  Other serious heart disease, such as congenital heart disease, rheumatic heart
             disease, hypertrophic or dilated heart disease,cardiac function(NYHA)
             classification&gt;level III.

          -  A history of acute complications such as diabetic ketoacidosis or hypertonic coma
             within 3 months.

          -  pregancy

          -  Allergic to sweeteners.

          -  participant in any clinical trail within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Ma, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Ma, professor</last_name>
    <phone>58752345</phone>
    <phone_ext>3083</phone_ext>
    <email>cherry1996@live.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 30, 2019</study_first_submitted>
  <study_first_submitted_qc>November 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>November 30, 2019</last_update_submitted>
  <last_update_submitted_qc>November 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>artificial sweetners</keyword>
  <keyword>glucose metabolism</keyword>
  <keyword>type 2 diabetic patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

